A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects with International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects with International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Siltuximab (Primary)
  • Indications Anaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 03 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 04 Jul 2012 New source identified and integrated (Memorial Sloan-Kettering Cancer Center; 12-057).
    • 14 Feb 2012 Planned End Date changed from 26 Aug 2012 to 30 Nov 2013, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top